Comparative Pharmacology
Head-to-head clinical analysis: ANDEMBRY versus FOLLISTIM AQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDEMBRY versus FOLLISTIM AQ.
ANDEMBRY vs FOLLISTIM AQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Recombinant human follicle-stimulating hormone (FSH) that binds to FSH receptors on granulosa cells in the ovary, stimulating follicular growth and maturation via activation of adenylyl cyclase and increased cAMP production.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
75 to 300 IU subcutaneously once daily for 8 to 14 days, adjusted based on follicular response; maximum daily dose 450 IU and total duration not exceeding 14 days per cycle.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Terminal elimination half-life approximately 24-36 hours (subcutaneous route); clinical context supports daily dosing due to sustained follicular stimulation.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Primarily renal (90%), with intact follitropin alfa/beta and metabolites excreted in urine; biliary/fecal excretion minimal (<10%).
Category C
Category C
Gonadotropin
Gonadotropin